Bubendorf, Switzerland, Saturday, June 5, 2021 – CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS Pharma’s innovation reduces the trade-off between efficacy and safety, inherent to MPDS that cover the complete contact lens care regimen with just one product.
CIS Pharma technology combines the use of three disinfectants that synergistically offer a high disinfection power. The chosen disinfectants result in shorter disinfection times and offer efficacy even if the lens wearer does not comply with the instructions for use, e.g. re-uses the same solution over time. In addition to the higher disinfection power, the technology allows for higher concentrations of comforting agents, such as hyaluronic acid, HA, in comparison to state-of-the-art products. Higher concentrations of HA have a positive effect on corneal health and comfort when inserting and wearing contact lenses. Corneal epithelial cells show higher migration and proliferation. Also HA is released from the contact lens over a longer period of time. CIS Pharma has an expertise of over 30 years in the contact lens care market, licensing and manufacturing products to market leaders in eye care.
About contact lens care
Contact lenses are medical devices and must be treated carefully. If lenses pick up dirt, they may transfer bacteria that can cause serious infections to the cornea. A multipurpose contact lens care solution effectively kills harmful bacteria and fungi while the lenses are stored. This is achieved by a mixture of powerful anti-infectives. In addition, multipurpose solutions remove various deposits such as lipid and protein aggregates from the lens surface. Other agents in multipurpose solutions are responsible for rewetting the lens to restore the wear comfort.
About CIS Pharma AG
CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. CIS Pharma is located in the life science cluster of Basel, Switzerland. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of currently used medical treatments. For more information about the company, visit our website www.cis-pharma.com. — Discovery is our business, progress our passion.